Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC).

被引：1

作者：

Lee, Chung-Han

Shah, Amishi Yogesh

Hsieh, James J.

Rao, Arpit

Pinto, Alvaro

Bilen, Mehmet Asim

Cohn, Allen Lee

Di Simone, Christopher

Shaffer, David R.

Sarrio, Regina Girones

Ribe, Sara Gunnestad

Wu, Jane

Schmidt, Emmett, V

Perini, Rodolfo F.

Kubiak, Peter

Smith, Alan D.

Motzer, Robert J.

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Univ Texas Houston, MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA

[3] Washington Univ, Sch Med, St Louis, MO USA

[4] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA

[5] Hosp Univ La Paz, Madrid, Spain

[6] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[7] Rocky Mt Canc Ctr, Denver, CO USA

[8] Arizona Oncol Associates, Tucson, AZ USA

[9] New York Oncol Hematol, Albany, NY USA

[10] Hosp Univ & Politecn La FE, Med Oncol Serv, Valencia, Spain

[11] Sorlandet Hosp Kristiansand, Kristiansand, Norway

[12] Eisai Inc, Woodcliff Lake, NJ USA

[13] Merck & Co Inc, Kenilworth, NJ USA

[14] Eisai Ltd, Hatfield, Herts, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5008

引用

页数：2

共 50 条

[31] PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation
Joseph, Richard W.
Millis, Sherri Z.
Carballido, Estrella M.
Bryant, David
Gatalica, Zoran
Reddy, Sandeep
Bryce, Alan H.
Vogelzang, Nicholas J.
Stanton, Melissa L.
Castle, Erik P.
Ho, Thai H.
CANCER IMMUNOLOGY RESEARCH, 2015, 3 (12) : 1303 - 1307
[32] PD1/PD-L1 therapy in metastatic renal cell carcinoma
Bruchbacher, Andreas
Lemberger, Ursula
Hassler, Melanie R.
Fajkovic, Harun
Schmidinger, Manuela
CURRENT OPINION IN UROLOGY, 2020, 30 (04) : 534 - 541
[33] PD-1/PD-L1 in Renal Cell Carcinoma: Projecting the Way Forward
Pal, Sumanta K.
Singh, Parminder
Vogelzang, Nicholas J.
CLINICAL GENITOURINARY CANCER, 2015, 13 (04) : 257 - 260
[34] Role of Nivolumab in the Modulation of PD-1 and PD-L1 Expression in Papillary and Clear Cell Renal Carcinoma (RCC)
Bialek, Joanna
Yankulov, Stefan
Kawan, Felix
Fornara, Paolo
Theil, Gerit
BIOMEDICINES, 2022, 10 (12)
[35] New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies
Grimm, Marc-Oliver
Leucht, Katharina
Gruenwald, Viktor
Foller, Susan
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (02)
[36] PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
Aaron Goodman
Sandip P. Patel
Razelle Kurzrock
Nature Reviews Clinical Oncology, 2017, 14 : 203 - 220
[37] Keratoacanthoma and Cutaneous Squamous Cell Carcinoma With PD-1 and PD-L1 Inhibitor Use
Aggarwal, Pushkar
Clark, Denise
Shah, Aatman
Rismiller, Kyle
Neltner, Scott A.
JAMA DERMATOLOGY, 2024, 160 (05) : 573 - 575
[38] Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma
Xingming Zhang
Xiaoxue Yin
Haoran Zhang
Guangxi Sun
Yaojing Yang
Junru Chen
Xudong Zhu
Peng Zhao
Jinge Zhao
Jiandong Liu
Ni Chen
Jia Wang
Pengfei Shen
Hao Zeng
BMC Cancer, 19
[39] Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma
Zhang, Xingming
Yin, Xiaoxue
Zhang, Haoran
Sun, Guangxi
Yang, Yaojing
Chen, Junru
Zhu, Xudong
Zhao, Peng
Zhao, Jinge
Liu, Jiandong
Chen, Ni
Wang, Jia
Shen, Pengfei
Zeng, Hao
BMC CANCER, 2019, 19 (1)
[40] PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?
Erlmeier, Franziska
Hartmann, Arndt
Autenrieth, Michael
Wiedemann, Max
Ivanyi, Philipp
Steffens, Sandra
Weichert, Wilko
MEDICAL ONCOLOGY, 2016, 33 (11)

← 1 2 3 4 5 →